Genetically engineered Bifidobacterium shows potential for oral delivery of cancer vaccines

A novel oral vaccine platform using genetically engineered Bifidobacterium could enhance anti-tumor immunity.

In an exploratory Phase I clinical study, the vaccine was well tolerated and generated immunologic and clinical findings that warrant further investigation.

The results also point to potential biomarkers that may help identify patients most likely to benefit from this approach. ...